AI Summary & Key Takeaways
AI InsightThe difference in parenchymal-lesion contrast is more prominent for metastatic liver lesions in the hepatocellular phase in patients administered Gd-EOB-DTPA.
📌 3 Key Takeaways
Özet
To compare Gadoxetic acid and Gadobenate dimeglumine in the detection and characterization of liver masses. In this study, 59 lesions in 28 patients are included in which were dynamic MRI that had been used Gadoxetic acid (Gd-EOB-DTPA) and Gadobenate dimeglumine (Gd-BOPTA). Observers recorded the liver lesions and adjacent parenchymal signal intensities (SI) in precontrast, arterial and hepatocyte phase by using the ROIs for the quantitative analysis. All statistical analyzes were performed with SPSS 22 software. p <0.05 was considered significant. In the cases of hemangiomas Gd-BOPTA applied, the SI of the lesions increased by 7.46% in the transition to the arterial phase, and 74.6% in the transition to the hepatocyte phase. In the cases of Gd-EOB-DTPA applied, the SI of the lesions increased by 16.01% in the transi-tion to the arterial phase, and 99.76% in the transition to the hepatocyte phase. Compared two agents in the arterial and the hepatocyte phases there were no statistically significant differences. In the cases of metastases Gd-BOPTA applied, the SI of the lesions increased by 28.10% in the transition to the arterial phase, and 90.48% in the transition to the hepatocyte phase. In the cases of Gd-EOB-DTPA applied, the SI of the lesions increased by 12.68 % in the transition to the arterial phase, and 47.72% in the transition to the hepatocyte phase. Compared two agents in the hepatocyte phase the p-value was 0.006 and found a statistically significant difference. The difference in parenchymal-lesion contrast is more prominent for metastatic liver lesions in the hepatocellular phase in patients administered Gd-EOB-DTPA.